Investigating a new target for cancer immunotherapy
PAG is a novel target in immunotherapy
['FUNDING_R01'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-10892185
This study is looking at a protein called PAG to see if targeting it can make cancer immunotherapy work better for more patients, helping their immune system fight off cancer more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10892185 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing cancer immunotherapy by targeting a protein called PAG, which plays a crucial role in the PD-1 immune checkpoint signaling pathway. By blocking PD-1, current therapies can help the immune system recognize and eliminate cancer cells, but not all patients benefit from these treatments. The study aims to validate PAG as a new target that could improve the effectiveness of immunotherapies for various cancers. Researchers will use advanced techniques to understand how PAG functions and how it can be manipulated to enhance T cell activity against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers such as bladder or breast cancer who may not have responded to existing immunotherapies.
Not a fit: Patients with cancers that are not influenced by PD-1 signaling or those who have already benefited from current immunotherapies may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for cancer patients, potentially improving their treatment outcomes.
How similar studies have performed: Previous research has shown promise in targeting immune checkpoints, but the specific focus on PAG as a novel target is relatively new and untested.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOR, ADAM — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: MOR, ADAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer